Differences in early dynamics of serum bone markers in women with postmenopausal osteoporosis treated by alendronate or risedronate

C. Sferrazza, Di Fede G, Daniel G. Fernández‐Ávila(University of Toronto), Loredana Sutera, Rini Gb, Cannone, Enrico Carmina(OHB (Italy))

Nova Science Publishers (Nova Science Publishers, Inc.)

January 1, 2004

Cited by 0

Related Papers

Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group

|Fertility and Sterility|2011|2k

Polycystic ovary syndrome

|Nature Reviews Disease Primers|2016|1.9k

American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome - Part 1

|Endocrine Practice|2015|628

Polycystic Ovary Syndrome (PCOS): Arguably the Most Common Endocrinopathy Is Associated with Significant Morbidity in Women

|The Journal of Clinical Endocrinology & Metabolism|1999|508

Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis

|Fertility and Sterility|2011|469